• FDA approves Actemra subcutaneous injection for active systemic JIA

    7 monthes ago - By Healio

    Sandra Horning
    The FDA has approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release from Genentech.
    Often characterized by inflammation in one or more joints, and a daily, spiking fever for at least 2 weeks that is sometimes accompanied by a skin rash, systemic juvenile idiopathic arthritis is the rarest form of juvenile arthritis, affecting approximately 30,000 children in the United States. Prior studies have determined that other accompanying symptoms can include
    Read more ...